Eton Pharmaceuticals P/E Ratio

Eton Pharmaceuticals's p/e ratio stands at 122.75. That is above the Healthcare sector average of 24.78. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Eton Pharmaceuticals sits higher the Healthcare benchmark (24.78) with a P/E ratio of 122.75. That is roughly 395.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 122.75 is attractive depends on Eton Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Eton Pharmaceuticals's P/E ratio evolved across reporting periods, while the comparison chart places ETON next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Eton Pharmaceuticals's reading of 122.75 (sector avg 24.78) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.